Baseline leptin cutpoints predictive of metreleptin response by RIA and ELISA assays in patients with lipodystrophy
Friday, September 15, 2017 — Poster Session IV
1:00 p.m. – 2:30 p.m.
FAES Terrace
NIDDK
PHARM-4
Authors
- N Malandrino
- B Abel
- S Auh
- M Walter
- M Startzell
- E Cochran
- P Gorden
- RJ Brown
Abstract
Introduction: Lipodystrophies are rare disorders characterized by deficient adipose tissue and low endogenous leptin concentrations, leading to severe metabolic complications. Treatment with recombinant human leptin (metreleptin) significantly improves metabolic complications, especially in patients with pre-treatment endogenous leptin
Category: Molecular Pharmacology